- Stories /
- Healthcare /
- Xellia /
![Axellia Køben Cfc0231 300Dpicmyk CROP](/media/lqknya1g/axellia_koeben_cfc0231_300dpicmyk_crop.jpg?width=616&height=370&v=1d9b33a52acc630)
![Xelia Logo NEW LHS](/media/u3qinh2s/xelia_logo_new_lhs.png?width=198&height=66&v=1d9c5429eb75a30)
Transformed from a supplier of niche active pharmaceutical ingredients to a fully-integrated speciality pharmaceutical company
![Denmark Flag New](/media/gxlheo1j/denmark_flag_new.png?width=50&height=50&v=1d9b33a9c47da50)
Investment date
2008 - 2013
Good to great
2.3x
money multiple>$100m
invested in R&D during investmentSuccessfully grew and transitioned the business to become a leader in the supply of key anti-infective products
11%
EBITDA growth per annumInvested more than $100m in R&D and capacity expansion across its global manufacturing network
Key events under our ownership
Established a high-calibre management team through our Business Leaders Network
Platform created for continued growth and enhanced margins, based on a broadened product range and an exciting pipeline of new products
Xellia’s focus on R&D resulted in 15 new product filings in the year prior to our sale
Expanded Xellia's global manufacturing network including a fill-finish plant in Copenhagen and a manufacturing plant in China to secure low-cost supply